WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience ScienceCareers.org
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (87)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, W. J.
Right arrow Articles by Walker, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, W. J.
Right arrow Articles by Walker, J. M.

 Previous Article  |  Next Article 

Volume 16, Number 20, Issue of October 15, 1996 pp. 6601-6611
Copyright ©1996 Society for Neuroscience

Suppression of Noxious Stimulus-Evoked Activity in the Ventral Posterolateral Nucleus of the Thalamus by a Cannabinoid Agonist: Correlation between Electrophysiological and Antinociceptive Effects

Received Feb. 26, 1996; revised July 24, 1996; accepted July 30, 1996.

William J. Martin, Andrea G. Hohmann, and J. Michael Walker

Schrier Research Laboratory, Department of Psychology, Brown University, Providence, Rhode Island 02912

The CNS contains a putative cannabinergic neurotransmitter and an abundance of G-protein-coupled cannabinoid receptors. However, little is known about the function of this novel neurochemical system. Cannabinoid agonists produce antinociception in behavioral tests, suggesting the possibility that this system serves in part to modulate pain sensitivity. To explore this possibility, the effects of the cannabinoid agonist WIN 55,212-2 on nociceptive neurons in the ventroposterolateral (VPL) nucleus of the thalamus were examined in urethane-anesthetized rats. After identification of a nociresponsive neuron, a computer-controlled device delivered graded pressure stimuli to the contralateral hindpaw. WIN 55,212-2 (0.0625, 0.125, and 0.25 mg/kg, i.v.) suppressed noxious stimulus-evoked activity of VPL neurons in a dose-dependent and reversible manner. Noxious stimulus-evoked firing was affected more than spontaneous firing. These effects were apparently mediated by cannabinoid receptors, because the cannabinoid receptor-inactive enantiomer of the drug (WIN 55,212-3, 0.25 mg/kg) failed to alter the activity of this population of cells. Administration of morphine (0.5 mg/kg, i.v.) produced effects that were very similar to those produced by the cannabinoid. WIN 55,212-2 (0.25 mg/kg, i.v.) failed to alter the responses of non-nociceptive low-threshold mechanosensitive neurons in the VPL. WIN 55,212-2 produced antinociceptive effects with a potency and time course similar to that observed in the electrophysiological experiments, despite the differences in the anesthetic states of the animals used in these experiments. The antinociceptive and electrophysiological effects on VPL neurons outlasted the motor effects of the drug. Furthermore, the changes in nociceptive responding could not be attributed to changes in skin temperature. Taken together, these findings suggest that cannabinoids decrease nociceptive neurotransmission at the level of the thalamus and that one function of endogenous cannabinoids may be to modulate pain sensitivity.

Key words: cannabinoid analgesia; tetrahydrocannabinol; anandamide; thalamus; nociception; rat




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
K. Benamar, E. B. Geller, and M. W. Adler
First in Vivo Evidence for a Functional Interaction between Chemokine and Cannabinoid Systems in the Brain
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 641 - 645.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
C. Liu and J. M. Walker
Effects of a Cannabinoid Agonist on Spinal Nociceptive Neurons in a Rodent Model of Neuropathic Pain
J Neurophysiol, December 1, 2006; 96(6): 2984 - 2994.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
A. G. Nackley, A. M. Zvonok, A. Makriyannis, and A. G. Hohmann
Activation of Cannabinoid CB2 Receptors Suppresses C-Fiber Responses and Windup in Spinal Wide Dynamic Range Neurons in the Absence and Presence of Inflammation
J Neurophysiol, December 1, 2004; 92(6): 3562 - 3574.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
Y.-C. Liang, C.-C. Huang, K.-S. Hsu, and T. Takahashi
Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices
J. Physiol., February 15, 2004; 555(1): 85 - 96.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
T. F. FREUND, I. KATONA, and D. PIOMELLI
Role of Endogenous Cannabinoids in Synaptic Signaling
Physiol Rev, July 1, 2003; 83(3): 1017 - 1066.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
V. Morisset and L. Urban
Cannabinoid-Induced Presynaptic Inhibition of Glutamatergic EPSCs in Substantia Gelatinosa Neurons of the Rat Spinal Cord
J Neurophysiol, July 1, 2001; 86(1): 40 - 48.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Straiker, N. Stella, D. Piomelli, K. Mackie, H. J. Karten, and G. Maguire
Cannabinoid CB1 receptors and ligands in vertebrate retina: Localization and function of an endogenous signaling system
PNAS, December 7, 1999; 96(25): 14565 - 14570.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. M. Walker, S. M. Huang, N. M. Strangman, K. Tsou, and M. C. Sanudo-Pena
Pain modulation by release of the endogenous cannabinoid anandamide
PNAS, October 12, 1999; 96(21): 12198 - 12203.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
A. J. Straiker, G. Maguire, K. Mackie, and J. Lindsey
Localization of Cannabinoid CB1 Receptors in the Human Anterior Eye and Retina
Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2442 - 2448.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
N. M. Strangman and J. M. Walker
Cannabinoid WIN 55,212-2 Inhibits the Activity-Dependent Facilitation of Spinal Nociceptive Responses
J Neurophysiol, July 1, 1999; 82(1): 472 - 477.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Zimmer, A. M. Zimmer, A. G. Hohmann, M. Herkenham, and T. I. Bonner
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
PNAS, May 11, 1999; 96(10): 5780 - 5785.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
A. G. Hohmann, K. Tsou, and J. M. Walker
Cannabinoid Suppression of Noxious Heat-Evoked Activity in Wide Dynamic Range Neurons in the Lumbar Dorsal Horn of the Rat
J Neurophysiol, February 1, 1999; 81(2): 575 - 583.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. H. Friedel, H. Schnurch, J. Stubbusch, and Y.-A. Barde
Identification of genes differentially expressed by nerve growth factor- and neurotrophin-3-dependent sensory neurons
PNAS, November 11, 1997; 94(23): 12670 - 12675.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-